-
ULikeKorea, Sumitomo sign deal on Japanese pet care marketIndustryJan 21, 2021ULikeKorea on Thursday announced that it had signed a memorandum of understanding with Sumitomo Corporation Korea to develop a health care tracker chip for pets in Japan. While existing microchip im... -
Experts discuss how Korean biotech firms can attract US investmentsIndustryJan 21, 2021Exactly a week after the year’s biggest global investor relations event JP Morgan Healthcare Conference wrapped up on Jan. 14, Korean biotech firms were still more than eager to pitch their businesse... -
Korea eyes Novavax deal for 20 million people: MoonIndustryJan 20, 2021South Korea may be able to secure additional vaccines for 20 million people from US drugmaker Novavax, President Moon Jae-in said Wednesday. The deal is still under negotiation, Moon said, while ear... -
GC Pharma to apply for COVID-19 plasma therapy EUA in AprilIndustryJan 20, 2021Drug maker GC Pharma will apply to expedite the use of its plasma-derived COVID-19 treatment in April in Korea, the company said on Wednesday. The plasma therapy, GC5131A, which uses donated blood p... -
Boryung revs up anti-cancer drug production line at Yesan plantIndustryJan 19, 2021Boryung Pharmaceutical announced it had begun full-fledged use of its Yesan plant and more emphasis on anti-cancer products. Boryung announced Tuesday that it had been producing plasma cell myeloma ... -
CJ Logistics floated for vaccine distributionIndustryJan 19, 2021As eyes turn toward the imminent start of COVID-19 inoculations, CJ Logistics has emerged as a candidate for vaccine distribution. CJ Logistics had been considered at a disadvantage, as it does not ... -
Celltrion’s COVID drug given green light in 1st of 3-step reviewIndustryJan 18, 2021Celltrion’s proposed COVID-19 treatment has won an OK in the first of the three-leg review by the Ministry of Food and Drug Safety, the agency said Monday. The Korean drugmaker last week sought cond... -
Hanmi touts production capacity for COVID-19 vaccinesIndustryJan 18, 2021The second building completed construction in 2019 as a six-story building with a total floor area of some 28,200 square meters. This second building is equipped with a state-of-the-art facility that... -
Yuhan’s lung cancer treatment lazertinib wins approvalIndustryJan 18, 2021The title for Korea’s 31st homegrown novel drug goes to Yuhan’s lung cancer treatment, Leclaza. On Monday, the Ministry of Food and Drug Safety announced its approval for the third-generation non-sm... -
![[Herald Interview] Oral health care in the hands of consumers](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=649&simg=/content/image/2021/01/17/20210117000017_0.jpg)
[Herald Interview] Oral health care in the hands of consumersIndustryJan 17, 2021“Health is not about something that is in hospital. In fact, it is something that could be addressed earlier. One‘s health has much to do with lifestyle choices,” said Deeptha Khanna, head of persona... -
LG, SK’s battery biz butt heads over US patent nullification suitIndustryJan 15, 2021LG Energy Solution and SK Innovation are yet again butting heads, this time over freshly launched inter partes review they both filed against each other at the US Patent and Trademark Office. An int... -
Samsung’s SmartTag technology threatens to outpace Apple innovationIndustryJan 15, 2021Bid adieu to panicky moments of lost keys or pets. Samsung Electronics‘s SmartTag technology, enabling users to locate what’s precious and dear to them, began generating buzz around the tech sphere F... -
Made-in-Korea COVID-19 treatments ready to hit marketIndustryJan 14, 2021One company after another, South Korea’s homegrown biopharmaceuticals are nearing emergency use approval for their proposed COVID-19 treatments. A day after Celltrion reported positive top-line data... -
Samsung Biologics’ new CEO lays out vision for next decadeIndustryJan 13, 2021Samsung Biologics’ newly appointed CEO John Rim presented a multidimensional vision for the company’s next 10 years at the virtual JP Morgan Healthcare Conference 2021 on Wednesday. Key takeaways fr... -
Celltrion's COVID-19 treatment reports clinical improvement of 54%TechnologyJan 13, 2021A coronavirus antibody treatment under development by local drugmaker Celltrion has shown a clinical improvement rate of 54 percent among mild and moderate COVID-19 cases, the company announced Wedne...
MOST POPULAR
-
01LG mulls exit from smartphone market
-
Biden takes office as 46th president of the US02
-
03Gyeonggi residents, including foreigners, to receive COVID-19 relief
-
Social distancing likely to persist through the year, says health minister04
-
05New virus cases in 400s for 2nd day amid downward trend
-
LG Group chief is richest Korean under 5006
-
07Two Koreas look toward new relationship with Biden
-
Korean language test for foreigners to take place 3 times abroad in 202108
-
09‘Child abuse is still a family matter, not a crime, in Korea’
-
Biden says will 'repair alliance,' lead world by power of example10